Chalcogen Bonded Directly To The Ring Carbon Para To The Ring Oxygen (e.g., Chromones, Etc.) Patents (Class 549/401)
  • Patent number: 9815809
    Abstract: The present invention relates to a synthesis of chromanones or chromanes in a stereospecific matter in view of the 2-position in the chromanone or chromane ring. It has been found that this synthesis is particularly possible in the presence of a chiral compound of formula of a specific type and of at least one phenol or thiophenol.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: November 14, 2017
    Assignee: DSM IP ASSETS B.V.
    Inventors: Ulla Letinois, Thomas Netscher
  • Patent number: 9809565
    Abstract: The present invention relates to a synthesis of chromanones or chromanes in a stereospecific matter in view of the 2-position in the chromanone or chromane ring. It has been found that this synthesis is particularly possible in the presence of a chiral compound of formula of a specific type and of at least one urea or thiourea.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: November 7, 2017
    Assignee: DSM IP ASSETS B.V.
    Inventors: Ulla Letinois, Thomas Netscher, Stephan Ackermann
  • Patent number: 9365660
    Abstract: A group of compounds defined by the general formula (I) can be used to anionically initiate polymerization of unsaturated monomers. In the formula, M is an alkali metal atom, R1 is an aryl group having at least one OR2 substituent group where each R2 is a group that is nonreactive toward M, and R is a hydrocarbyl group. The subject initiators can be used in semi-batch and continuous polymerization processes, even those which are performed at elevated temperatures.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: June 14, 2016
    Assignee: Bridgestone Corporation
    Inventors: Yuan-Yong Yan, Zengquan Qin, Xiao-Dong Pan, David M. Roggeman
  • Patent number: 9309216
    Abstract: The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives represented by formula (IA) and (IB), processes for preparing the alcohol derivatives and their use in preparing pharmaceuticals.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: April 12, 2016
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Jayaraman V. Raman, Swaroop K. Vakkalanka
  • Publication number: 20150141424
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 21, 2015
    Inventors: Qingping ZENG, Andras TORO, John Bruce PATTERSON, Warren Stanfield WADE, Zoltan ZUBOVICS, Yun YANG, Zhipeng WU
  • Patent number: 8987480
    Abstract: The present invention relates to a process of separating chiral isomers of chroman compounds, particularly tocopherols and tocotrienols as well as the esters and intermediates thereof. It has been found that this process allows a separation of the desired isomer with a higher yield and enables the use of the non-desired isomers in a very efficient way. Said process is particularly useful when implemented in an industrial process. Furthermore, it has been found that this process allows using isomer mixtures as they result from traditional industrial synthesis.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: March 24, 2015
    Assignee: DSM IP Assets B.V.
    Inventors: Gerhard Schiefer, Thomas Netscher, Alexander Lucia Leonardus Duchateau
  • Patent number: 8901323
    Abstract: Provided is a ruthenium complex that is represented by general formula (1*) and is useful as an asymmetric reduction catalyst. (In the formula, * is an asymmetric carbon atom; R1 is an arenesulfonyl group, and the like; R2 and R3 are a phenyl group, and the like; R10 through R14 are selected from a hydrogen atom, C1-10 alkyl group, and the like, but R10 through R14 are not simultaneously hydrogen atoms; X is a halogen atom and the like; j and k are each either 0 or 1; and j+k is 0 or 2.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: December 2, 2014
    Assignee: Takasago International Corporation
    Inventors: Taichiro Touge, Tomohiko Hakamata, Hideki Nara
  • Patent number: 8759547
    Abstract: A process for the extraction of Vitamin E from annatto plant matter is disclosed wherein annatto seed matter is subjected, before extraction, to acidification using amla fruit matter. After the acidification, the mixture of the two plant matters is extracted by water. The acidification converts the vitamin E compounds in the plant matter into more water-soluble forms, thus enhancing the vitamin yield. More of the vitamin is obtained in the ester form than in the form of vitamin alcohols. Processing time is reduced.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: June 24, 2014
    Inventors: Ramaswamy Rajendran, Kamala Rajendran
  • Publication number: 20140171455
    Abstract: Methods for deterring microglia-mediated neurotoxicity in a human or non-human animal subjects comprising the step of inhibiting or blocking the intermediate-conductance calcium-activated potassium channel Kv1.3 in microglia, such as in subjects how suffer from neurodegenerative diseases (e.g., Alzheimer's Disease) or ischemic/anoxic/hypoxic conditions. The inhibition or blocking of the KCa1.3 channels may be accomplished by administering a substance that inhibits Kv1.3 in microglia. Examples of Kv1.3 inhibiting substances include certain 5-phenoxyalkoxypsoralens, such as (4-Phenoxybutoxy)psoralen (PAP-1) as well as certain 4-phenoxybutoxy-substituted heterocyclic compounds.
    Type: Application
    Filed: June 8, 2012
    Publication date: June 19, 2014
    Applicant: The Regents of the University of California
    Inventors: Heike Wulff, Lee-Way Jin, Izumi Meezawa
  • Patent number: 8716497
    Abstract: A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: May 6, 2014
    Assignees: Children's Hospital Medical Center, Ausio Pharmaceuticals, Inc.
    Inventors: Kenneth David Reginald Setchell, Victor Dmitrievich Sorokin
  • Publication number: 20140051871
    Abstract: Provided is a ruthenium complex that is represented by general formula (1*) and is useful as an asymmetric reduction catalyst. (In the formula, * is an asymmetric carbon atom; R1 is an arenesulfonyl group, and the like; R2 and R3 are a phenyl group, and the like; R10 through R14 are selected from a hydrogen atom, C1-10 alkyl group, and the like, but R10 through R14 are not simultaneously hydrogen atoms; X is a halogen atom and the like; j and k are each either 0 or 1; and j+k is 0 or 2.
    Type: Application
    Filed: May 2, 2012
    Publication date: February 20, 2014
    Applicant: TAKASAGO INTERNATIONAL CORPORATION
    Inventors: Taichiro Touge, Tomohiko Hakamata, Hideki Nara
  • Patent number: 8629197
    Abstract: A chemically patterned modified hydrogel formed from a modified hydrogel is provided. The hydrogel is conjugated with a multiphoton photocleavable molecule. The molecule has a multiphoton-labile protective group and a protected group. The protective group is cleavable upon multiphoton excitation to deprotect the protected group, without substantial polymerization of the hydrogel. The chemically patterned modified hydrogel is formed by exposing the modified hydrogel to multiphoton excitation to deprotect a portion of the protected groups.
    Type: Grant
    Filed: April 7, 2008
    Date of Patent: January 14, 2014
    Inventors: Molly Shoichet, Jordan Wosnick, Ryan Wylie
  • Publication number: 20130303786
    Abstract: Disclosed is a benzylpiperizine compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a medicinal agent such as an antidepressant agent. (In the formula (1), R1 represents a hydrogen atom or a methyl group; R2 is a group bound in a p- or m-position relative to a methylene group and represents a chlorine atom bound in a p-position, a bromine atom bound in a p-position, a methyl group bound in a p-position, a chlorine atom bound in a m-position or a bromine atom bound to in a m-position; X represents a methylene or an oxygen atom; and n represents an integer of 1 to 3.
    Type: Application
    Filed: July 11, 2013
    Publication date: November 14, 2013
    Inventors: Tomohiro TOYODA, Hidefumi YOSHINAGA
  • Publication number: 20130287716
    Abstract: The present invention relates to chromen-4-one derivatives of the formula (I), to the use thereof as self-tanning substance or for increasing melanin synthesis, improving melanin transport and/or improving the distribution of melanin in suprabasal layers, and to preparations comprising these chromen-4-one derivatives.
    Type: Application
    Filed: December 27, 2011
    Publication date: October 31, 2013
    Applicant: MERCK PATENT GMBH
    Inventors: Christophe Carola, Rene Peter Scheurich
  • Publication number: 20130158276
    Abstract: Provided is a catalyst for asymmetric reduction, which can be produced by a convenient and safe production method, has a strong catalytic activity, and has excellent stereoselectivity. The present invention relates to a ruthenium complex represented by the following formula (1): wherein R1 represents an alkyl group or the like; Y represents a hydrogen atom; X represents a halogen atom or the like; j and k each represent 0 or 1; R2 and R3 each represent an alkyl group or the like; R11 to R19 each represent a hydrogen atom, an alkyl group or the like; Z represents oxygen or sulfur; n1 represents 1 or 2; and n2 represents an integer from 1 to 3, a method for producing the ruthenium complex, a catalyst for asymmetric reduction formed from the ruthenium complex, and methods for selectively producing an optically active alcohol and an optically active amine using the catalyst for asymmetric reduction.
    Type: Application
    Filed: June 17, 2011
    Publication date: June 20, 2013
    Applicant: TAKASAGO INTERNATIONAL CORPORATION
    Inventors: Taichiro Touge, Hideki Nara, Tomohiko Hakamada
  • Publication number: 20130096209
    Abstract: The present invention provides edible compositions comprising a compound of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of NaCl in a food product, methods of reducing the sodium intake in a diet, and methods of reducing bitter taste in a food product.
    Type: Application
    Filed: April 15, 2011
    Publication date: April 18, 2013
    Applicants: Kraft Foods Global Brands LLC, Chromocell Corporation
    Inventors: David Hayashi, William P. Jones, Jane V. Leland, Peter H. Brown, Joseph Gunnet, Daniel Lavery, Louise Slade, Kambiz Shekdar, Jessica Langer
  • Publication number: 20130028837
    Abstract: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.
    Type: Application
    Filed: August 10, 2012
    Publication date: January 31, 2013
    Applicant: Lantheus Medical Imaging, Inc.
    Inventors: Heike S. Radeke, David S. Casebier, Michael T. Azure, Douglas D. Dischino
  • Patent number: 8329928
    Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: December 11, 2012
    Assignee: Cytokinetics, Incorporated
    Inventors: Andrew McDonald, Gustave Bergnes, Bainian Feng, David J. Morgans, Jr., Steven David Knight, Kenneth A. Newlander, Dashyant Dhanak, Christopher A. Brook
  • Patent number: 8314070
    Abstract: This invention relates to certain Aloesin derivatives with natural amino acids, peptides, and amino sugars (formula I).
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: November 20, 2012
    Assignee: Island Kinetics, Inc.
    Inventors: Shyam K Gupta, Linda Walker
  • Publication number: 20120289496
    Abstract: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Application
    Filed: May 4, 2012
    Publication date: November 15, 2012
    Applicant: Rhizen Pharmaceuticals SA
    Inventors: Dhanapalan NAGARATHNAM, Swaroop Kumar V.S. Vakkalanka, Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Prashant K. Bhavar
  • Publication number: 20120289555
    Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.
    Type: Application
    Filed: February 10, 2011
    Publication date: November 15, 2012
    Applicant: N30 PHARMACEUTICALS, LLC
    Inventors: Xicheng Sun, Jian Qiu
  • Patent number: 8293928
    Abstract: The present invention is directed to compositions comprising fluorinated 4-oxo-chroman-carboxylates, particularly fluorinated 4-oxo-chroman-7-carboxylate, and a process for making the same. The compounds are useful as intermediates in the production of agricultural chemicals, and also as chain terminators in condensation polymerization reactions, particularly when it is desired to provide a polymer having a relatively low surface energy.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: October 23, 2012
    Assignee: E I du Pont de Nemours and Company
    Inventor: Neville Everton Drysdale
  • Publication number: 20120259122
    Abstract: Disclosed is a benzylpiperizine compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a medicinal agent such as an antidepressant agent. (In the formula (1), R1 represents a hydrogen atom or a methyl group; R2 is a group bound in a p- or m-position relative to a methylene group and represents a chlorine atom bound in a p-position, a bromine atom bound in a p-position, a methyl group bound in a p-position, a chlorine atom bound in a m-position or a bromine atom bound to in a m-position; X represents a methylene or an oxygen atom; and n represents an integer of 1 to 3.
    Type: Application
    Filed: June 20, 2012
    Publication date: October 11, 2012
    Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventors: Tomohiro TOYODA, Hidefumi YOSHINAGA
  • Patent number: 8273905
    Abstract: Compounds corresponding to formula I, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n have the meanings given in the description, and also a process for the preparation of these compounds and intermediate products of this process. Furthermore, pharmaceutical compositions comprising the compounds of Formula I and related methods of treatment.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: September 25, 2012
    Assignee: Abbott Products GmbH
    Inventors: Brian Moloney, Lester Marrison, Dieter Ziegler, Michael Mlinaric, Christiane Boecker, Reinhard Brueckner, Michael Weske, Klaus Witte, Yvan Fischer
  • Patent number: 8263790
    Abstract: A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: September 11, 2012
    Assignees: Children's Hospital Medical Center, Girindus America, Inc.
    Inventors: Kenneth David Reginald Setchell, Victor Dmitrievich Sorokin
  • Patent number: 8257981
    Abstract: Novel chemical compounds, with application in fluorometric analytical methods, for qualitative and quantitative determination of biomolecules. The aim of the invention is to identify and prove the suitability of such compounds. Said aim is achieved with compounds of formula (1) where R1 is an antenna function, R2 is a chelate forming agent, containing a coordinated lanthanide(III)ion, X is —OH or a group with affinity for the biomolecule, bonded to a carboxylate group of the chelate forming agent by means of an amide bond and Y is —H or a group with affinity for the biomolecule, coupled to the antenna function.
    Type: Grant
    Filed: April 30, 2005
    Date of Patent: September 4, 2012
    Assignee: Sensient Imaging Technologies GmbH
    Inventors: Jörg Marx, Frank Schumer, Regina Lischewski, Kornelia Zeckert, Hans-Joachim Böhme, Horst Hennig
  • Publication number: 20120209012
    Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
    Type: Application
    Filed: January 13, 2012
    Publication date: August 16, 2012
    Inventors: Andrew McDonald, Gustave Bergnes, Bainian Feng, David J. Morgans, JR., Steven David Knight, Kenneth A. Newlander, Dashyant Dhanak, Christopher A. Brook
  • Patent number: 8227511
    Abstract: The present invention relates to substituted chromanol derivatives, to processes for their preparation, to their use on their own or in combination for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: July 24, 2012
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Carsten Schmeck, Hilmar Bischoff, Volkhart Li, Klemens Lustig, Michael Thutewohl, Alexandros Vakalopoulos, Olaf Weber
  • Publication number: 20120070515
    Abstract: The present invention relates to a composition comprising an extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same, as an active ingredient. In particular, the extract and compounds have the excellent inhibitory effects on adipocyte differentiation, and thus can be used in a pharmaceutical composition and functional food for the prevention and treatment of lipid metabolism disorders.
    Type: Application
    Filed: December 8, 2009
    Publication date: March 22, 2012
    Applicant: EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION
    Inventors: Eun Kyoung Seo, Eun Sook Hwang, Ui Joung Youn, Joo Won Nam
  • Publication number: 20120071465
    Abstract: The present invention relates to the compounds useful in the prevention and/or treatment of tumours. More specifically the present invention relates to inhibitors of the activity of the electron transport chains and/or the mitochondrial TCA cycle in glioma-initiating cells (GICs) for use in a method for preventing and/or treating tumours presenting glioma-initiating cells (GICs) in a subject who has undergone a prior removal of a tumour glioma bulk. The present invention further provides a pharmaceutical composition containing the inhibitors of the invention and a screening method for identifying the inhibitors of the invention.
    Type: Application
    Filed: May 20, 2010
    Publication date: March 22, 2012
    Inventors: Virginie Clement, Ivan Radovanovic
  • Patent number: 8110688
    Abstract: It is possible to commercially advantageously prepare 1-{1-[2-(7-methoxy-2,2-dimethyl-4-oxochroman-8-y)ethyl]piperidin-4-yl}-N-methyl-1H-indole-6-carboxamide by coupling (7-methoxy-2,2-dimethyl-4-oxochroman-8-yl)acetaldehyde, which is obtained by oxidizing 8-(2-hydroxyethyl)-7-methoxy-2,2-dimethylchroman-4-one, with N-methyl-1-(piperidin-4-yl)-1H-indole-6-carboxamide.
    Type: Grant
    Filed: November 5, 2006
    Date of Patent: February 7, 2012
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Naoyuki Shimomura, Atsushi Kamada, Mamoru Miyazawa, Koichi Ito
  • Patent number: 8088935
    Abstract: Compounds and methods for the treatment of asthma are disclosed. The methods involve mast cell stabilization together with selective inhibition of iNOS. The compounds are combinations of a mast cell inhibiting moiety and an inhibitor of iNOS.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: January 3, 2012
    Assignee: Ironwood Pharmaceuticals, Inc.
    Inventors: James Pearson, John J. Talley, Mark G. Currie
  • Publication number: 20110282077
    Abstract: The object of the present invention is to solve the problems in the prior arts, and to find more improved reaction conditions for suppressing the racemization of the product and obtaining an optically active alcohol at a high optical purity. The inventors achieved to solve the above problems by using a solvent system that is capable of resolving both an asymmetric catalyst and a formate salt, allowing the hydrogen source and the asymmetric catalyst to be present in the same phase.
    Type: Application
    Filed: May 10, 2011
    Publication date: November 17, 2011
    Applicant: Kanto Kagaku Kabushiki Kaisha
    Inventors: Taito Hatakeyama, Kunihiko Murata, Kunihiko Tsutsumi, Noriyuki Utsumi
  • Publication number: 20110213166
    Abstract: The present invention is directed to compositions comprising fluorinated 4-oxo-chroman-carboxylates, particularly fluorinated 4-oxo-chroman-7-carboxylate, and a process for making the same. The compounds are useful as intermediates in the production of agricultural chemicals, and also as chain terminators in condensation polymerization reactions, particularly when it is desired to provide a polymer having a relatively low surface energy.
    Type: Application
    Filed: September 1, 2010
    Publication date: September 1, 2011
    Applicant: E.I. DU PONT DE NEMOURS AND COMPANY
    Inventor: Neville Everton Drysdale
  • Publication number: 20110207807
    Abstract: The present disclosure relates to a new use of homoisoflavanone or a salt thereof. More particularly, it relates to a pharmaceutical composition for the prevention and treatment of inflammatory diseases or allergic diseases comprising homoisoflavanone represented by Chemical Formula 1 or a salt thereof, a use of homoisoflavanone or a salt thereof in the manufacture of an agent for the preventing and treating of inflammatory diseases or allergic diseases, and a method for treating inflammatory diseases or allergic diseases including administering an effective dose of homoisoflavanone or a salt thereof to a subject in need thereof.
    Type: Application
    Filed: September 2, 2009
    Publication date: August 25, 2011
    Applicant: Catholic University Industry Academy Cooperation Foundation
    Inventors: Tae Yoon Kim, Dong Heon Shin
  • Patent number: 8003810
    Abstract: The present invention relates to a process for preparing Nebivolol and, more particularly, to an improved process for synthesizing enantiomerically enriched 6-fluoro chroman alcohol or epoxide derivatives of formula, wherein R and X is defined in the description; as useful intermediates in the preparation of Nebivolol.
    Type: Grant
    Filed: November 23, 2007
    Date of Patent: August 23, 2011
    Assignee: Zach System S.p.A.
    Inventors: Elio Ullucci, Paolo Maragni, Livius Cotarca, Johnny Foletto
  • Patent number: 7960573
    Abstract: A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.
    Type: Grant
    Filed: May 4, 2009
    Date of Patent: June 14, 2011
    Assignees: Children's Hospital Medical Center, Girindus America, Inc.
    Inventors: Kenneth David Reginald Setchell, Victor Dmitrievich Sorokin
  • Publication number: 20110136242
    Abstract: Novel chemical compounds, with application in fluorometric analytical methods, for qualitative and quantitative determination of biomolecules. The aim of the invention is to identify and prove the suitability of such compounds. Said aim is achieved with compounds of formula (1) where R? is an antenna function, R2 is a chelate forming agent, containing a coordinated lanthanide(III)ion, X is —OH or a group with affinity for the biomolecule, bonded to a carboxylate group of the chelate forming agent by means of an amide bond and Y is —H or a group with affinity for the biomolecule, coupled to the antenna function.
    Type: Application
    Filed: April 30, 2005
    Publication date: June 9, 2011
    Applicant: SENSIENT IMAGING TECHNOLOGIES GMBH
    Inventors: Jorg Marx, Frank Schumer, Regina Lischewski, Kornelia Zeckert, Hans-Joachim Bohme, Horst Hennig
  • Publication number: 20110124573
    Abstract: This invention relates to certain Aloesin derivatives with natural amino acids, peptides, and amino sugars (formula I).
    Type: Application
    Filed: January 28, 2011
    Publication date: May 26, 2011
    Applicant: Island Kinetics Inc.
    Inventors: SHYAM K. GUPTA, Linda Walker
  • Publication number: 20110117649
    Abstract: Various chromanone, flavanone and abyssinone compounds as can be prepared enantioselectively using a chiral thiourea catalyst.
    Type: Application
    Filed: December 13, 2010
    Publication date: May 19, 2011
    Inventors: Karl Scheidt, Margaret Marie Biddle
  • Patent number: 7910621
    Abstract: The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of XIAP family proteins. In particular, the present invention provides embelin and other XIAP inhibitors and methods of using these compounds as antagonists of the anti-apoptotic effects of XIAP family member proteins. The present invention also provides methods for treating diseases and pathologies (e.g., neoplastic diseases).
    Type: Grant
    Filed: March 22, 2005
    Date of Patent: March 22, 2011
    Assignee: The Regents of the University of Michigan
    Inventors: Jianyong Chen, Zaneta Nikolovska-Coleska, Dajun Yang, Shaomeng Wang, Haiying Sun, Liang Xu, Zengjian Hu
  • Publication number: 20110009646
    Abstract: There are provided a novel ruthenium-diamine complex, and methods for selectively producing an optically active alcohol and an optically active amine, which are important as precursors for the synthesis of medicinal drugs and functional materials, using the ruthenium-diamine complex as a catalyst. A novel ruthenium-diamine complex prepared by introducing a trisubstituted silyl group into an aromatic compound (arene) moiety that is coordinated with a ruthenium complex having an optically active diamine as a ligand, a catalyst for asymmetric reduction formed from the ruthenium-diamine complex, and a method for producing an optically active alcohol or an optically active amine using the catalyst.
    Type: Application
    Filed: July 13, 2010
    Publication date: January 13, 2011
    Applicant: TAKASAGO INTERNATIONAL CORPORATION
    Inventors: Taichiro Touge, Hideki Nara
  • Patent number: 7851640
    Abstract: Various chromanone, flavanone and abyssinone compounds as can be prepared enantioselectively using a chiral thiourea catalyst.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: December 14, 2010
    Assignee: Northwestern University
    Inventors: Karl Scheidt, Margaret Marie Biddle
  • Patent number: 7838553
    Abstract: The present invention is directed to novel benzopyran derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: November 23, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Xuqing Zhang, Xiaojie Li, Zhihua Sui
  • Patent number: 7812183
    Abstract: The present invention is directed to novel benzopyran derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.
    Type: Grant
    Filed: August 30, 2006
    Date of Patent: October 12, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Xuqing Zhang, Xiaojie Li, Zhihua Sui
  • Publication number: 20100217009
    Abstract: A process for preparing a compound of formula (22), comprising reducing a compound of formula (21), to produce a compound of formula (23), followed by the hydrogenolysis of the compound of formula 23 in a solvent comprising a C1 to C6 alkyl sulfonic acid and optionally a chlorinated solvent.
    Type: Application
    Filed: May 21, 2008
    Publication date: August 26, 2010
    Applicant: BIAL - PORTELA & CA, S.A.
    Inventors: David Alexander Learmonth, Alexander Beliaev
  • Patent number: 7754759
    Abstract: Compounds of the formula I: wherein m, n, p, X, Ar, R1, R2, R3, R4 and R5 are as defined herein. Methods of making the compounds and using the compounds for treatment of 5-HT6 receptor-mediated diseases are disclosed.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: July 13, 2010
    Assignee: Roche Palo Alto LLC
    Inventors: Jacob Berger, Joan Marie Caroon, Francisco Javier Lopez-Tapia, Lee Edwin Lowrie, Jr., Dov Nitzan, Shu-Hai Zhao
  • Publication number: 20100160268
    Abstract: A pharmacologic agent for treating and/or preventing cancer, among other diseases and conditions, and particularly breast, prostate, and pancreatic cancer, in humans and animals. The novel pharmacologic agent is an isoflavonoid or isoflavonoid mimetic covalently attached to a cytotoxic pharmacophore that, preferably has the ability to conjugate with a metal salt to form a more potent metal complex, particularly a Cu(II) complex. The isoflavonoid or isoflavonoid mimetic may he non-fragmented steroidal hormone, such as progesterone which is structurally related to the isoflavone genistein, or a small molecule hormone mimetic, such as chromone. An illustrative non-fragmented steroidal embodiment is 17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,13,14,15, 16,17-tetradecahydrocyclopenta[a]phenanthren-3-thiosemicarbazone and its Cu(II) complex. Effective chromone analogs include the thiosemicarbazone and hydrazone analogs of 4-oxo-4H-chromene-3-carboxaldehyde and their Cu(IT) complexes.
    Type: Application
    Filed: September 25, 2006
    Publication date: June 24, 2010
    Inventors: Sarkar Fazlul, Subhash Padhye
  • Patent number: 7714150
    Abstract: Compounds corresponding to formula I, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n have the meanings given in the description, and also a process for the preparation of these compounds and intermediate products of this process. Furthermore, pharmaceutical compositions comprising the compounds of Formula I and related methods of treatment.
    Type: Grant
    Filed: April 10, 2006
    Date of Patent: May 11, 2010
    Assignee: Solvay Pharmaceuticals GmbH
    Inventors: Brian Moloney, Lester Marrison, Dieter Ziegler, Michael Mlinaric, Christiane Boecker, Reinhard Brueckner, Michael Weske, Klaus Witte, Yvan Fischer
  • Publication number: 20100076206
    Abstract: The present invention relates to a process for preparing Nebivolol and, more particularly, to an improved process for synthesizing enantiomerically enriched 6-fluoro chroman alcohol or epoxide derivatives of formula, wherein R and X is defined in the description; as useful intermediates in the preparation of Nebivolol.
    Type: Application
    Filed: November 23, 2007
    Publication date: March 25, 2010
    Applicant: ZACH SYSTEM S.P.A.
    Inventors: Elio Ullucci, Paolo Maragni, Livius Cotarca, Johnny Foletto